Published online before print April 14, 2003, doi: 10.1161/01.HYP.0000068201.48340.3B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:1136.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Cyclosporin A Disrupts Bradykinin Signaling Through Superoxide
From the Department of Medicine, Division of Hypertension, Case Western Reserve University (M.V., Z.-J.C., D.C., S.L., C.-H.C.), Cleveland, Ohio; the Department of Medicine, Reproductive Research Center, Shandong Provincial Hospital, Shandong University (Z.-J.C.), Jinan, Peoples Republic of China; and the Graduate Institute of Biological Sciences, National Taiwan University (G.-D.C.), Taipei, Taiwan.
Correspondence to Dr Chung-Ho Chang, Department of Medicine, Division of Hypertension, Case Western Reserve University School of Medicine, 2109 Adelbert Road, Room W165, Cleveland, OH 44106. E-mail cxc13{at}po.cwru.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Cyclosporin A (CsA) is used to reduce transplant rejection rates. Chronic use, however, has a destructive toxic effect on the kidney, resulting in hypertension. In this study, we investigated the effects of CsA treatment on the bradykinin/soluble guanylate cyclase signaling cascade and the involvement of superoxide in LLC-PK1 porcine kidney proximal tubule cells. Treatment with 1 µmol/L CsA for 24 hours increased basal cGMP levels by 41%, whereas CsA inhibited bradykinin-stimulated cGMP production by 26%. Western blotting showed increased expression of eNOS, but no other protein in the bradykinin/soluble guanylate cyclase (sGC) pathway was affected. Using lucigenin-dependent chemiluminescence, we found that CsA treatment significantly increased superoxide production. Production of O2- was not significantly reduced by 10 µmol/L oxypurinol or 30 µmol/L ketoconazole. However, it was inhibited by the NADPH oxidase inhibitor diphenyleneiodonium chloride (10 µmol/L) as well as the O2- scavenger superoxide dismutase (SOD) (100 U). On treatment with 50 µmol/L quercetin, 10 mmol/L N-acetyl-cysteine, both antioxidants, as well as the O2- scavenger Tiron (10 mmol/L), concomitant with 1 µmol/L CsA for 24 hours the activation of cGMP production, was restored in combination with a reduction in O2-. Incubation with 100 µmol/L menadione, a reactive oxygen generator, and 10 nmol/L bradykinin showed similar effects on the level of cGMP as with CsA. CsA treatment was found to increase nitrotyrosine levels. These findings suggest that CsA activates a NADPH oxidase that releases O2- and disrupts the bradykinin/soluble guanylate cyclase pathway, probably by binding with NO to form peroxynitrite (ONOO-).
Key Words: cyclosporin • bradykinin • nitric oxide • cyclic GMP • antioxidants
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cyclosporin (CsA) is an important immunosuppressant used in improving the chances of whole organ transplant and graft survival.1,2 However, cyclosporin treatment has been linked to several significant nephrotoxic side effects. The side effects range from afferent arteriolar constriction3 and a reduction in glomerular filtration rate4 to interstitial fibrosis5 and ultimately hypertension. Although the toxic effects are well established, the exact mechanisms that lead to the pathology and hypertension are not agreed on. The proposed mechanisms for the development of hypertension focus on induction of vasoconstrictive pathways as well as obstruction of vasodilative pathways examined in patients, rat models, and endothelial cells. The pathways examined as possibly affected by CsA include the renal sensory nerve endings,6 the renin-angiotensin system,7 endothelin-1,8,9 thromboxane,9,10 and the renal kallikrein-kinin system.11,12
Bradykinin is an important vasodilating peptide involved in the renal kallikrein-kinin system. The bradykinin peptide exerts its effects by binding to its receptor, activating a heterotrimeric G protein complex, phospholipase C, and then nitric oxide synthase (eNOS), which generates nitric oxide (NO). NO then binds to the heme group of soluble guanylate cyclase (sGC), thereby activating the enzyme to produce cGMP.13,14 The NO synthase family and the NO radical have been shown to play an important role in many biological processes including maintaining cardiovascular tone15 and ion balance.16 Several studies have attempted to link NO17,18 and the bradykinin pathway11,12 to CsA-induced hypertension, but no clear answer regarding the involvement of either has been reached.
Besides NO, another free radical, the superoxide anion (O2-), also has been shown to play an important role in renal and vascular physiology.19 It is well accepted that treatment with CsA causes an increase in production of O2- and that the anion is related to some of the secondary pathological effects of CsA. However, questions still remain as to how the oxygen radical is formed and the physiological result of its production.20 To further investigate the side effects of cyclosporin, we set out to determine a correlation between the nephrotoxic effect of CsA, the bradykinin/sGC pathway, and the possible involvement of NADPH oxidase produced O2- in LLC-PK1 porcine proximal tubular cells. Our results demonstrate that CsA activates a membrane NADPH oxidase that results in the formation of superoxide and decreases bradykinin/sGC signaling.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
cGMP Determination
LLC-PK1 cells were grown to confluence in 6-well (35-mm) plates with RPMI medium (pH 7.3) containing 10% horse serum, 5% fetal bovine serum, and 1% Pen/Strep. The cells were washed with 2 mL of serum-free RPMI medium and then incubated with 1 µmol/L cyclosporin and/or 50 µmol/L quercetin, 10 mmol/L Tiron, and 10 mmol/L NAC for 24 hours at 37°C. The medium was then removed and the cells were incubated with 900 µL of RPMI containing 0.5 mmol/L isobutylmethylxanthine for 10 minutes at 37°C; 10 nmol/L bradykinin and/or 100 µmol/L menadione was then added to the cells and incubated for 10 minutes. After incubation, the medium was aspirated and 1 mL of cold 10% trichloroacetic acid was added to each well. The cell extracts were scraped, then centrifuged for 15 minutes at 2000g. The supernatants were then extracted with water-saturated ether to remove the trichloroacetic acid. The cGMP levels in the supernatants were then determined by radioimmunoassay as previously described.21,22
Western Blotting
LLC-PK1 cells were grown to confluence in 25-cm2 flasks in the previously described RPMI media. They were then washed with serum-free RPMI media and treated for 24 hours with 1 µmol/L CsA and/or 50 µmol/L quercetin, 10 mmol/L Tiron, 10 µmol/L DPI, and 10 mmol/L NAC at 37°C. To prepare whole-cell lysates, the cells were lysed by 1% Triton X-100 in 50 mmol/L Tris-HCL buffer (pH 7.6) containing 5 mmol/L dithiothreitol, 0.2 mmol/L phenylmethylsulfonyl fluoride, aprotinin (10 µg/mL), and leupeptin (10 µg/mL). To prepare membrane and cytosolic fractions, the cells were lysed with 25 mmol/L Tris-HCL (pH 7.6), 250 mmol/L sucrose, containing 5 mmol/L dithiothreitol, 0.2 mmol/L phenylmethylsulfonyl fluoride, aprotinin (10 µg/mL), and leupeptin (10 µg/mL). The lysates (20 µg) were subjected to SDS-PAGE and transferred to a PVDF membrane. The membrane was blocked with 3% bovine serum albumin in 50 mmol/L Tris (pH 8.5), 0.1% sodium azide, and 150 mmol/L NaCl. The PVDF membrane was then incubated with bradykinin-B2 receptor (Transduction Laboratory, 1:1000), Gq
(Calbiochem, 1:4000), Gß1 (Calbiochem, 1:1000), G
2 (Calbiochem, 1:1000), phospholipase C-ß1(Transduction Laboratory, 1:1000), 26-1 (Upstate Biotech, 1:1000), eNOS, iNOS, nNOS (Transduction Laboratory, 1:2500), sGC (raised against amino acids 581 to 595 of the 70-kDa subunit of bovine sGC22), p47phox, p67phox (Transduction Laboratory, 1:500), Rac1 (Santa Cruz, 1:1000), or nitrotyrosine (Upstate Biotech, 1:1000) at 4°C for 4 hours. After primary antibody incubation, the PVDF membrane was washed 3 times with saline (50 mmol/L Tris buffer (pH 8.5) containing 150 mmol/L NaCl) plus 0.1% Tween 20. The membrane was then incubated with horseradish peroxidase–conjugated goat anti-rabbit or anti-mouse IgG (1:2500) dilution for 1 hour at room temperature. The immunoreactive proteins were visualized by enhanced chemiluminescence.
NADPH/Superoxide Assay
LLC-PK1 cells were grown to confluence in 6-well plates and treated with 1 µmol/L cyclosporin and/or 10 µmol/L DPI, 100 U SOD, 100 µmol/L menadione, 30 µmol/L ketoconazole, 10 µmol/L oxypurinol, 10 mmol/L Tiron, 10 mmol/L NAC, or 50 µmol/L quercetin for 24 hours at 37°C. The cells were then washed twice with ice-cold PBS. The cells were then scraped and suspended in 500 µL of homogenization buffer containing 20 mmol/L K2HPO4, 1 mmol/L EGTA, aprotinin (10 µg/mL), leupeptin (10 µg/mL), and 1 mmol/L phenylmethylsulfonyl fluoride. The suspension was homogenated with 50 strokes in a Dounce homogenizer on ice. The activity of NADPH oxidase was then determined by lucigenin-dependent chemiluminescence (LDC), as previously described.23,24 Briefly, 900 µL of an assay buffer containing 50 mmol/L NaHPO4, 1 mmol/L EGTA, 150 mmol/L sucrose, 5 µmol/L lucigenin (Sigma), and 100 µmol/L NADPH was added to 100 µL of the cell homogenate. Chemiluminescent photoemission was determined in relative light units (RLU) with the use of a Lumat LB 9501 Luminometer.
Statistics
Densitometry of all Western blots was performed with UN-SCAN-IT software from Silk Scientific. All densitometry data were then normalized with ß-actin staining. All statistical analysis was done with the Student t test. A probability value of <0.05 was assumed to be significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Bradykinin/sGC Signaling Pathway Is Impaired by Cyclosporin Treatment
To determine the effects of CsA treatment on the bradykinin/sGC pathway, we measured the production of bradykinin-stimulated cGMP in LLC-PK1 cells. Addition of 10 nmol/L bradykinin for 10 minutes to the cells increased the cGMP
2-fold (Figure 1). Incubation with 1 µmol/L CsA for 24 hours increased the cGMP production by 1.5-fold. However, 24-hour pretreatment of the cells with 1 µmol/L CsA significantly reduced the activation of sGC by bradykinin.
|
0.001 vs basal control, P
Impairment of Bradykinin/sGC Signaling Is Not Due to Change in Protein Expression
We next investigated the possibility of CsA-stimulated expression differences in the bradykinin pathway component proteins. Western blotting showed that the expression of bradykinin-B2 receptor, Gq, Gß1, G2, phospholipase C (ß and ), and sGC was not affected by 24-hour treatment with 1 µmol/L CsA (Figure 2A). In contrast, eNOS expression was significantly increased (Figure 2B). These results indicate that CsA does not inhibit the sGC signaling by decreasing protein expression.
|
Cyclosporin Treatment Activates NADPH Oxidase to Release Superoxide
CsA has been shown to produce O2- in several in vivo and in vitro studies. Therefore, we examined the possible role of NADPH oxidase and the production of O2- in blocking the bradykinin pathway. We found that CsA treatment significantly increased the production of O2-. Protein from experimental samples was added to assay buffer without the NADPH nucleotide, labeled "buffer," to show that the O2- release was from an oxidase dependent on the NADPH nucleotide. Menadione, an exogenous source of O2-, was added to demonstrate the effectiveness of the assay to detect O2- (Figure 3A). Western blotting was performed to verify the expression of the component proteins of the NADPH oxidase system, p47phox, p67phox, and Rac1 in LLC-PK1 cells (Figure 3B). No significant difference was found in their expression levels (data not shown). To further confirm activation of the NADPH oxidase by CsA, Western blotting on membrane and cytosolic fractions was performed (Figure 3C). We observed that treatment with CsA resulted in translocation of the Rac1 protein from the cytosol to the membrane (Figure 3D).
|
Menadione Treatment Mimics the Effects of Cyclosporin on cGMP
To determine the correlation between O2- and the reduction of cGMP production, we investigated the effects of addition of exogenous O2-; 10 nmol/L of bradykinin alone increased cGMP by 2-fold. Incubation of the cells with 100 µmol/L menadione decreased basal cGMP production by 29%. Menadione also decreased the bradykinin-stimulated cGMP production to a level not significantly different from the basal menadione-treated cells (Figure 4). This demonstrates the ability of superoxide to disrupt the bradykinin signaling pathway.
|
Cyclosporin Effect on Bradykinin-Stimulated cGMP Production Is Reversible With Antioxidants, Quercetin and NAC, and the Superoxide Scavenger Tiron
To further confirm the involvement of O2- in the disruption of the pathway, we examined the effects of antioxidants and superoxide scavengers. Figure 5 shows that treatment of LLC-PK1 cells with 10 nmol/L bradykinin gives a 1.8-fold increase in activation of sGC as compared with untreated cells (Figure 5). Preincubation with 1 µmol/L CsA decreased the bradykinin-stimulated activity of cGMP production to only a 1.1-fold increase in activation. Coincubation of the cells with 1 µmol/L CsA and 50 µmol/L quercetin, 10 mmol/L NAC, or 10 mmol/L Tiron returned the bradykinin-stimulated sGC activation to 1.6-, 1.75-, and 1.65-fold that of untreated cells, respectively.
|
Superoxide Scavengers, Antioxidants, and Oxidase Inhibitors Reduce CsA-Induced Superoxide Release
Because the cGMP production was restored by treatment with quercetin, NAC, and Tiron, we investigated whether the same chemicals would effect the detection of superoxide (Figure 6). We observed that concomitant treatment with 1 µmol/L CsA and 50 µmol/L quercetin, 10 mmol/L NAC, or 10 mmol/L Tiron decreased the amount of O2-. The significant reduction in luminescence on treatment with SOD further confirmed that the luminescence observed is due to the detection of O2-. Basal treatment with the chemicals alone showed a decrease or no significant difference in superoxide production (data not shown). To determine the exact oxidase involved, we utilized several oxidase inhibitors. Neither ketoconazole (30 µmol/L), an inhibitor of the cytochrome P450 system, nor oxypurinol (10 µmol/L), a xanthine oxidase inhibitor, was able to significantly reduce the release of O2-. We then examined the effect of the NADPH oxidase inhibitor DPI. We found that 10 minutes of treatment with 10 µmol/L DPI significantly decreased the O2- production by CsA.
|
P
CsA Treatment Increases Nitrotyrosine Residues
Because superoxide and nitric oxide are known to bind to form peroxynitrite, which in turn nitrosylates tyrosine residues, we examined the levels of nitrotyrosine in control and CsA-treated cells. Western blotting showed increased levels of nitrotyrosine after CsA treatment (Figure 7A). Densitometry analysis showed that these levels were reduced by the antioxidants quercetin and NAC, the superoxide scavenger Tiron, the NADPH oxidase inhibitor DPI, and the peroxynitrite scavenger uric acid (Figure 7B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
CsA has long been used as an immunosuppressant after organ graft to reduce the chances of graft rejection. However, the clinical use of CsA has consistently led to severe side effects, most significantly nephrotoxicity and hypertension. Though the pathology of CsA treatment is evident, the mechanisms that lead to its development are still unclear and disputed. In the current study, we investigated the role of NADPH oxidase in the adverse effects of CsA treatment on porcine kidney proximal tubule cells. We discovered that in these cells, chronic CsA treatment disrupts the bradykinin/sGC pathway through a NADPH dependent oxidase production of superoxide.
Bradykinin, and the kallikrein-kinin system in general, is an important peptide signaling system involved in maintaining vascular tone.25 Bradykinin exerts its effects by activating eNOS to produce NO, which binds and activates sGC.13,14 Though the involvement of the bradykinin system in CsA-induced nephrotoxicity has been discussed in the literature, the conclusions to be drawn are unclear. Wang et al11 suggest that there is an increase in expression of bradykinin (B2) receptor mRNA in renal tissue to compensate for CsA-induced hypertension, whereas Bompart et al12 concluded that CsA reduces the expression of bradykinin (B2) receptor mRNA in the renal cortex, leading to or aggravating the renal effects of CsA treatment. In our current study, in the proximal tubule, at a protein level, we found no expression difference in the bradykinin-B2 receptor. These discrepancies could simply be due to the different tissues and cells used in the various studies. Our data, however, do show that chronic treatment with CsA significantly reduces the amount of bradykinin-stimulated cGMP, signifying a disruption of the signaling cascade downstream of the receptor within the proximal tubule.
The bradykinin-signaling pathway from the receptor to sGC involves several proteins. It is possible that the diminished bradykinin signaling after CsA treatment may be due to altered expression of one of these component proteins. However, Western blotting showed that of the component proteins, only eNOS expression was altered. Our data and other studies26 demonstrated that CsA can increase eNOS expression. We found no expression difference of iNOS or nNOS (data not shown). Consistent with the eNOS data, we also observed an increase in cGMP with CsA treatment, which would lead to the conclusion that there is an increase in NO production. Other groups have also shown this increase in NO. In bovine aortic endothelial cells, using cell permeable fluorescent dyes, Navarro-Antolin et al27 were able to detect NO production and showed that CsA increases intracellular NO. However, Lima et al18 detected a decreased nitrite level from the media of cultured LLC-PK1 cells after 72 hours of CsA treatment. This study, as well as others, uses an indirect extracellular method to determine the production level of NO that may have been altered or quenched by other biochemical or physiological processes. In contrast, our study used the activation of the NO target enzyme sGC as a determination of NO production. Therefore, CsA may increase the expression of eNOS and thereby the release of NO in basal conditions, but the free radical messenger is somehow quenched before reaching sGC in a bradykinin-stimulated situation.
Superoxide (O2-) has been described to be a prominent component of many signaling pathways as well as a disease risk factor.28,29 Using a lucigenin-based chemiluminescent assay, we were able to show that CsA treatment increased O2- production. We were able to further confirm that the increase in luminescence is caused by O2- by showing that treatment with SOD and the oxygen radical scavenger Tiron decreases the amount of luminescence. Our data also show that the release of O2- is dependent on the presence of the NADPH nucleotide, furthering the conclusion that the O2- is produced by a NADPH oxidase. NADPH oxidase systems are membrane oxidases that have been well described in immune and vascular cells.29 Recently, the component proteins for a NADPH oxidase system, which include p47phox, p67phox, and Rac1, have been described in the kidney.30,31 We found that the p47, p67, and Rac1 subunits are expressed in LLC-PK1 cells. Besides showing the expression of the subunits, we were able to demonstrate that CsA treatment triggered translocation of the Rac1 protein from the cytosol to the membrane, signifying activation of the oxidase. To further confirm the involvement of the NADPH oxidase system in the CsA-induced production of O2-, we used the NADPH oxidase inhibitor DPI. We found that DPI significantly blocked the release of O2-.
To further isolate NADPH oxidase as the system producing the O2-, we examined other O2--producing pathways. Xanthine oxidase is another cellular system that is known to produce O2-. By using the xanthine oxidase inhibitor oxypurinol, we were able to show that xanthine oxidase does not account for the production of O2- in our system. It has also been proposed by several groups that the release of O2- is brought on by the cytochrome P450 (CYP) metabolism of CsA.32 By using an inhibitor of the CYP pathway, ketoconazole, we demonstrated that the observed CsA-induced O2- production is not caused by CYP metabolism of CsA. This conclusion is supported by several factors, primarily that CsA is metabolized by the CYP3A4 isoform of CYP; however, it has been shown that within the kidney, CYP3A5 rather than CYP3A4 is the major CYP isoform.33 In fact, in CsA-treated renal microsomes, the ability to metabolize CsA was 30 times lower than that in similarly treated hepatic microsomes.34 Also, in electron spin resonance studies performed on rats treated with CsA, it was discovered that the oxygen radicals found in the urine were not resulting from metabolites of CsA, though those found in the bile did resemble CsA metabolites.35,36
The decrease in NO-stimulated sGC activity resulting from CsA treatment can then be explained by its interaction with the NADPH oxidase produced O2-. NO, in vivo, is known to quickly bind to O2- to form the strong oxidant peroxynitrite (ONOO-). NO has such a high affinity for the superoxide anion that it has been shown to compete with SOD for binding of O2-.15 It has even recently been shown that CsA treatment can induce the formation of peroxynitrite, dependent on the concentration of superoxide anion.37 Peroxynitrite has been shown to interact with proteins and produce nitrotyrosine residues.15 Through the use of a nitrotyrosine antibody, we are able to clearly show that CsA treatment significantly increases the amount of nitrotyrosine (see Figure 7). Our data also show that the formation of nitrotyrosine is inhibited by the addition of the NADPH oxidase inhibitor DPI, the antioxidant NAC, as well as the oxygen radical scavenger Tiron and the peroxynitrite scavenger uric acid. Therefore, it is likely that the release of O2- by CsA treatment quenches NO through peroxynitrite formation, thereby disrupting the bradykinin/sGC signaling.
Examining the effects of altering the balance of the 2 radicals can further this conclusion. Several studies have shown that addition of L-arginine (L-arg) to CsA-treated systems can block some of the nephrotoxic effects. Yang et al38 showed in whole rats that cotreatment with CsA and L-arg reduced the amount of fibrosis and tubular injury while increasing the GFR and NO level. Addition of exogenous L-arg provides abundant substrate for eNOS. Since O2- is the limiting reactant in the formation of peroxynitrite, extra L-arg allows the system to produce more NO than O2- and allows the signaling cascade to continue. It is also possible to reverse the peroxynitrite formation by reducing the O2-. Quercetin is known to be a strong antioxidant that can scavenge free radicals in vivo, and it has recently been reported that quercetin can decrease oxidative stress caused by CsA treatment.39 In our study, we found that concomitant treatment of the cells with quercetin or NAC and CsA restored some of the bradykinin signaling as well as decreasing the release of CsA-induced O2- and subsequently peroxynitrite. We can then conclude that the addition of quercetin and NAC quenches some CsA-induced superoxide, allowing the NO to bind to sGC to form cGMP. We have also shown that the addition of exogenous O2- can mimic the blocking effects of CsA treatment. Cellular reduction of menadione causes the release of significant amounts of O2-. We showed that addition of menadione to basal and bradykinin-challenged cells blocks cGMP production. Since O2- has been shown to be the limiting factor in the formation of peroxynitrite, saturating the system with O2- blocks almost all NO signaling to the sGC enzyme. The ability of menadione to block cGMP production and antioxidants to restore it emphasizes the importance of O2- in the CsA disruption of the bradykinin/sGC pathway.
The pathology of CsA has mostly been examined in the vasculature and smooth muscle. However, in our study and others, CsA treatment has also been shown to have direct effects on the tubules of the kidney. Other studies with LLC-PK1 cells have shown that CsA causes a loss of cell-cell adhesion40 as well as inducing growth arrest and cell death.41 In the conditions of the current study, no significant loss of viability was observed. Our study proposes that within the proximal tubule, some the pathology resulting from CsA treatment might be due to a blocking of signaling by superoxide production. The bradykinin-sGC pathway has several important physiological functions in the maintenance of blood pressure. Though its most significant role is in regulating vascular tone, it also has been shown to have direct effects on ion balance within the kidney. Several studies have shown that a disruption of bradykinin signaling inhibits the kidney’s ability to excrete excess sodium.42 More specifically, NO is an important aspect of the bradykinin pathway. The disruption of the bradykinin signaling and the evidence of peroxynitrite formation suggest that NO has been quenched. A reduction of NO within the proximal tubule has been shown to disrupt the activity of Na+/ATPase and Na+/H+ exchangers and ultimately affect the permeability of the proximal tubule membrane.17 Similar disruptions of ion balance mechanisms have been observed by peroxynitrite formation.43 Through the use of LLC-PK1 proximal tubule cells, we were able to show that CsA treatment increases the production of O2-, which in turn blocks bradykinin signaling and quenches NO through the production of peroxynitrite. Though further study is needed to determine the direct importance of these components in blood pressure and ion maintenance within the proximal tubule, the ability of CsA to disrupt their physiological function suggests several pathways from which CsA pathology might arise.
Perspectives
Since its physiological functions were described, CsA has been widely used clinically. Despite its ability to improve survival rates and reduce rejections after organ transplants, it has been shown to have a wide range of pathological side effects. The current study shows that chronic treatment with CsA blocks bradykinin signaling in the proximal tubule through NADPH oxidase produced superoxide and the subsequent formation of peroxynitrite. These signaling pathways and radicals play many important roles in the vasculature as well as kidney tubules. The demonstration of the disruption of the balances in these signaling mechanisms by CsA describes them as a new candidate to be considered in the many pathways that lead to CsA pathology.
|
Acknowledgments |
|---|
This work was supported by grants from the National Institutes of Health (RO1 HL-56791 and PO1 HL-41618) and the American Heart Association (9740121N and 0255135B).
Received October 23, 2002; first decision November 12, 2002; accepted March 13, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Borel JF. Mechanisms of action of cyclosporin A and rationale for use in nephritic syndrome. Clin Nephrol. 1991; 35 (suppl 1): S23–S30.[Medline] [Order article via Infotrieve]
2. Jain A, Khanna A, Molmenti EP, Rishi N, Fung JJ. Immunosuppressive therapy. Surg Clin North Am. 1999; 79: 59–76.[CrossRef][Medline] [Order article via Infotrieve]
3. Takenaka T, Hashimoto Y, Epstein M. Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporin-treated rats. J Am Soc Nephrol. 1992; 3: 42–50.[Abstract]
4. Perico N, Remuzzi A, Imberti O, Cavallotti D, Bertani T, Remuzzi G. Morphometrical analysis of glomerular changes induced by cyclosporin in the rat. Am J Kidney Dis. 1991; 17: 537–543.[Medline] [Order article via Infotrieve]
5. Vieira JM Jr, Noronha IL, Malheiros DM, Burdmann EA. Cyclosporin induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation. 1999; 68: 1746–1753.[CrossRef][Medline] [Order article via Infotrieve]
6. Zhang W, Li JL, Hosaka M, Janz R, Shelton JM, Albright GM, Richardson JA, Sudhof TC, Victor RG. Cyclosporin A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A. 2000; 97: 9765–9770.
7. Lassila M. Interaction of cyclosporin A and the renin-angiotensin system: new perspectives. Curr Drug Metab. 2002; 3: 61–71.[CrossRef][Medline] [Order article via Infotrieve]
8. Rezzani R, Rodella L, Bianchi R. Induction of endothelin in rat kidney after cyclosporin A treatment. Acta Histochem. 2001; 103: 423–431.[CrossRef][Medline] [Order article via Infotrieve]
9. Darlametsos IE, Papanikolaou EN, Varonos DD. Effect of nifedipine in cyclosporin-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems. Prostaglandins Leukot Essent Fatty Acids. 2000; 63: 263–269.[Medline] [Order article via Infotrieve]
10. Averna M, Barbagallo CM, Ganci A, Giammarresi C, Cefalu AB, Sparacino V, Caputo F, Basili S, Notarbartolo A, Davi G. Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney Int. 2001; 59: 1574–1579.[Medline] [Order article via Infotrieve]
11. Wang C, Ford P, Chao C, Chao L, Chao J. Effect of cyclosporin A on the expression of tissue kallikrein, kininogen and bradykinin receptor in rat. Am J Physiol. 1997; 273: F783–F789.[Medline] [Order article via Infotrieve]
12. Bompart G, Tack I, Castano EM, Pesquero JB, Girolami JP, Bascands JL. Cyclosporin A decreases kallikrein and BK2 mRNA expression in the rat renal cortex. Immunopharmacology. 1996; 32: 99–101.[CrossRef][Medline] [Order article via Infotrieve]
13. Hall JM. Bradykinin receptors. Gen Pharmacol. 1997; 28: 1–6.[Medline] [Order article via Infotrieve]
14. Mateo AO, de Artinano MA. Nitric oxide reactivity and mechanisms involved in its biological effects. Pharmacol Res. 2000; 42: 421–427.[CrossRef][Medline] [Order article via Infotrieve]
15. Murad F, Leitman D, Waldman S, Chang CH, Hirata M, Kohse K. Effects of nitrovasodilators, endothelium-dependent vasodilators and atrial peptides on cGMP. Cold Spring Harbor Symp Quant Biol. 1998; 53: 1005–1009.
16. Liang M, Knox FG. Production and functional roles of nitric oxide in the proximal tubule. Am J Physiol Regul Integr Comp Physiol. 2000; 278: R1117–R1124.
17. Oriji GK, Keiser HR. Role of nitric oxide in cyclosporin A-induced hypertension. Hypertension. 1998; 32: 849–855.
18. Lima R, Serone AP, Schor N, Higa EM. Effect of cyclosporin A on nitric oxide production in cultured LLC-PK1 cells. Ren Fail. 2001; 23: 43–52.[CrossRef][Medline] [Order article via Infotrieve]
19. Andreoli SP. Reactive oxygen molecules, oxidant injury and renal disease. Pediatr Nephrol. 1991; 5: 733–742.[CrossRef][Medline] [Order article via Infotrieve]
20. Buetler TM, Cottet-Maire F, Krauskopf A, Ruegg UT. Does cyclosporin A generate free radicals. Trends Pharmacol Sci. 2000; 21: 288–290.[CrossRef][Medline] [Order article via Infotrieve]
21. Chen ZJ, Vetter M, Che D, Liu S, Tsai ML, Chang CH. The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells. Cancer Lett. 2002; 77: 181–187.
22. Miao ZH, Song DL, Douglas JG, Chang CH. Mutational inactivation of the catalytic domain of guanylate cyclase-A receptor. Hypertension. 1995; 25: 694–698.
23. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001; 38: 1107–1111.
24. Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA. Validation of Lucigenin (Bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998; 273: 2015–2023.
25. Hornig B, Drexler H. Endothelial function and bradykinin in humans. Drugs. 1997; 54 (suppl 5): 42–47.[Medline] [Order article via Infotrieve]
26. Lopez-Ongil S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol M, Lamas S. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol. 1996; 271: H1072–H1078.[Medline] [Order article via Infotrieve]
27. Navarro-Antolin J, Lamas S. Nitrosative stress by cyclosporin A in the endothelium: studies with the NO-sensitive probe diaminofluorescein-2/diacetate using flow cytometry. Nephrol Dial Transplant. 2001; 16 (suppl 1): 6–9.
28. Guzic TJ, West NEJ, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000; 86: e85–e90.[Medline] [Order article via Infotrieve]
29. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.
30. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002; 39: 269–274.
31. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of Renox, an NADPH oxidase in kidney. Proc Natl Acad Sci U S A. 2000; 97: 8010–8014.
32. Ahmed SS, Napoli KL, Strobel HW. Oxygen radical formation during cytochrome P450-catalyzed cyclosporin metabolism in rat and human liver microsomes at varying hydrogen ion concentrations. Mol Cell Biochem. 1995; 151: 131–140.[CrossRef][Medline] [Order article via Infotrieve]
33. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmakinet. 1999; 37: 485–505.
34. Pham-Huy C, Sadeg N, Becue T, Martin C, Mahuzier G, Warnet JM, Hamon M, Cluade JR. In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS. Arch Toxicol. 1995; 69: 346–349.[Medline] [Order article via Infotrieve]
35. Zhong Z, Arteel GE, Connnor HD, Yin M, Frankenberger MV, Stachlewitz RF, Raleigh JA, Mason RP, Thurman RG. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Am J Physiol. 1998; 275: F595–F604.[Medline] [Order article via Infotrieve]
36. Zhong Z, Connor HD, Yin M, Moss N, Mason RP, Bunzendahl H, Forman DT, Thurman RG. Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol Pharmacol. 1999; 56: 455–463.
37. Navarro-Antolin J, Lopez-Munoz MJ, Soria J, Lamas S. Superoxide limits cyclosporin-A-induced formation of peroxynitrite in endothelial cells. Free Radic Biol Med. 2002; 32: 702–711.[CrossRef][Medline] [Order article via Infotrieve]
38. Yang CW, Kim YS, Kim J, Kim YO, Min SY, Choi EJ, Bang BK. Oral supplementation of L-arginine prevents chronic cyclosporin nephrotoxicity in rats. Exp Nephrol. 1998; 6: 50–56.[CrossRef][Medline] [Order article via Infotrieve]
39. Satyanarayana PS, Singh D, Chopra K. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporin in rats. Methods Find Exp Clin Pharmacol. 2001; 23: 175–181.[CrossRef][Medline] [Order article via Infotrieve]
40. Zimmerhackl LB, Mesa H, Kramer F, Kolmel C, Wiegele G, Brandis M. Tubular toxicity of cyclosporin A and the influence of endothelin-1 in renal cell culture models (LLC-PK1 and MDCK). Pediatr Nephrol. 1997; 11: 778–783.[CrossRef][Medline] [Order article via Infotrieve]
41. Lally C, Healy E, Ryan MP. Cyclosporin A-induced cell cycle arrest and cell death in renal epithelial cells. Kidney Int. 1999; 56: 1254–1257.[CrossRef][Medline] [Order article via Infotrieve]
42. Katori M, Majima M, Hayashi I. Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension. Biol Res. 1998; 31: 143–149.[CrossRef][Medline] [Order article via Infotrieve]
43. Zhang C, Imam SZ, Ali SF, Mayeux PR. Peroxynitrite and the regulation of Na(+), K(+)-ATPase activity by angiotensin II in the rat proximal tubule. Nitric Oxide. 2002; 7: 30–35.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. K. Khanna and G. M. Pieper NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model Nephrol. Dial. Transplant., February 1, 2007; 22(2): 376 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-J. Chen, M. Vetter, G.-D. Chang, S. Liu, D. Che, Y. Ding, S. S. Kim, and C.-H. Chang Cyclophilin A Functions as an Endogenous Inhibitor for Membrane-Bound Guanylate Cyclase-A Hypertension, December 1, 2004; 44(6): 963 - 968. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||